Management and Outcomes of Heart Failure Patients with CKD: Experience from an Inter-Disciplinary Clinic
Open Access
- 11 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (5) , 3225-3230
Abstract
Aims CKD‐HF patients suffer excess hospitalization and mortality, often under‐treated with life‐prolonging medications due to fear of worsening renal function and hyperkalaemia. Yet, role of inter‐disciplinary working in improving therapy is unknown, which this study aims to investigate. Methods and results Clinical, biochemical data, and medications at first and last clinic visit were obtained from patient records for 124 patients seen in kidney failure–heart failure clinic (23 March 2017 to 11 April 2019). Medication dose groups (none, low, and high dose), number of RAASi agents, and blood test results were compared between first and last visit in patients with at least two clinic visits (n = 97). Patient characteristics were age 78.5 years (IQR 68.1–84.4 years), male 67.7%, diabetes 51.6%, moderate (45.2%) vs. severe (39.5%) CKD, HF with reduced ejection fraction (HFrEF) (49.2%), follow‐up 234 days (IQR 121–441 days). HFrEF was associated with increased risk of death (adjusted OR 4.49, 95% CI 1.43–14.05; P = 0.01). Distributions of patients according to number of RAASi agents they were on differed between first and last visit (P = 0.03). Dosage was increased in 25.9% for beta‐blockers, 33.0% for ACEi/ARBs, and 17.5% for MRAs. Distributions of patients across MRA dosage groups was different (P = 0.03), with higher proportions on higher dosages at last visit, without significant changes in serum potassium or creatinine. Serum ferritin improved (131.0 vs. 267.5 μg/L; P < 0.001), and fewer patients had iron deficiency (56.7% vs. 26.8%; P = 0.002) at last visit compared to the first. Conclusions This inter‐disciplinary clinic improved guideline‐recommended medication prescription, MRA dosages in CKD‐HF patients without significant biochemical abnormality, and iron status. A prospectively designed study with medication titration protocol and defined patient‐centred outcomes is needed to further assess effectiveness of such clinic.Keywords
Funding Information
- George's Academic Training
- Welcome ISSF
- British Heart Foundation (PG 10/71/28462)
- British Heart Foundation (PG 10/71/28462)
This publication has 16 references indexed in Scilit:
- Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2019
- Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney diseaseAmerican Heart Journal, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Interdisciplinary care clinics in chronic kidney diseaseBMC Nephrology, 2015
- Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal InsufficiencyJACC, 2014
- Influence of Renal Function on the Use of Guideline-Recommended Therapies for Patients With Heart FailureThe American Journal of Cardiology, 2010
- Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialThe Lancet, 2003
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987